V
Vaxcell Bio Therapeutics
KOSDAQ:323990
Vaxcell Bio Therapeutics
KOSDAQ:323990
Price:
9 340
KRW
-1.58%
Market Closed
Market Cap:
₩217.2B
Balance Sheet
Balance Sheet Decomposition
Vaxcell Bio Therapeutics
Vaxcell Bio Therapeutics
Balance Sheet Decomposition is not available for
Vaxcell Bio Therapeutics
Vaxcell Bio Therapeutics
Balance Sheet
Vaxcell Bio Therapeutics
Vaxcell Bio Therapeutics
Currency: KRW
| Dec-2018 | Dec-2019 | Dec-2020 | Dec-2021 | Dec-2022 | Dec-2023 | Dec-2024 | ||
|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||
| Cash & Cash Equivalents |
4 446
|
4 074
|
9 903
|
2 309
|
390
|
9 046
|
7 821
|
|
| Cash |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Cash Equivalents |
4 446
|
4 074
|
9 903
|
2 309
|
390
|
9 046
|
7 821
|
|
| Short-Term Investments |
7 001
|
4 000
|
9 000
|
25 000
|
20 002
|
41 000
|
27 688
|
|
| Total Receivables |
91
|
120
|
112
|
374
|
291
|
715
|
2 257
|
|
| Accounts Receivables |
26
|
28
|
39
|
229
|
126
|
383
|
1 803
|
|
| Other Receivables |
65
|
92
|
73
|
145
|
165
|
332
|
454
|
|
| Inventory |
0
|
0
|
0
|
0
|
0
|
97
|
238
|
|
| Other Current Assets |
8
|
123
|
172
|
515
|
216
|
369
|
1 102
|
|
| Total Current Assets |
11 546
|
8 317
|
19 186
|
28 197
|
20 898
|
51 227
|
39 105
|
|
| PP&E Net |
677
|
1 557
|
1 142
|
2 804
|
2 541
|
2 674
|
6 509
|
|
| PP&E Gross |
677
|
1 557
|
1 142
|
2 804
|
2 541
|
2 674
|
6 509
|
|
| Accumulated Depreciation |
301
|
530
|
1 136
|
1 644
|
1 657
|
2 241
|
3 497
|
|
| Intangible Assets |
2
|
77
|
69
|
148
|
229
|
207
|
2 341
|
|
| Goodwill |
0
|
0
|
0
|
0
|
0
|
0
|
2 449
|
|
| Note Receivable |
0
|
0
|
0
|
0
|
0
|
0
|
290
|
|
| Long-Term Investments |
0
|
0
|
15 000
|
0
|
0
|
29 873
|
14 920
|
|
| Other Long-Term Assets |
33
|
83
|
101
|
127
|
494
|
999
|
11 330
|
|
| Other Assets |
0
|
0
|
0
|
0
|
0
|
0
|
2 449
|
|
| Total Assets |
12 258
N/A
|
10 036
-18%
|
35 498
+254%
|
31 276
-12%
|
24 163
-23%
|
84 980
+252%
|
76 944
-9%
|
|
| Liabilities | ||||||||
| Accounts Payable |
0
|
0
|
0
|
0
|
0
|
0
|
478
|
|
| Accrued Liabilities |
31
|
222
|
189
|
129
|
118
|
118
|
263
|
|
| Short-Term Debt |
3 378
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Current Portion of Long-Term Debt |
0
|
163
|
186
|
183
|
47
|
217
|
865
|
|
| Other Current Liabilities |
11 720
|
41
|
219
|
80
|
142
|
589
|
1 213
|
|
| Total Current Liabilities |
15 129
|
426
|
594
|
392
|
307
|
924
|
2 820
|
|
| Long-Term Debt |
8 906
|
301
|
153
|
37
|
59
|
144
|
1 403
|
|
| Other Liabilities |
419
|
238
|
83
|
766
|
470
|
418
|
727
|
|
| Total Liabilities |
24 453
N/A
|
964
-96%
|
830
-14%
|
1 196
+44%
|
836
-30%
|
1 487
+78%
|
4 950
+233%
|
|
| Equity | ||||||||
| Common Stock |
1 773
|
3 254
|
3 762
|
7 612
|
7 612
|
11 497
|
11 497
|
|
| Retained Earnings |
15 886
|
17 359
|
21 288
|
26 505
|
33 383
|
43 537
|
54 413
|
|
| Additional Paid In Capital |
1 919
|
23 054
|
51 913
|
48 888
|
48 888
|
115 619
|
115 619
|
|
| Treasury Stock |
0
|
0
|
0
|
0
|
0
|
533
|
1 365
|
|
| Other Equity |
0
|
121
|
280
|
85
|
210
|
448
|
656
|
|
| Total Equity |
12 195
N/A
|
9 071
N/A
|
34 667
+282%
|
30 080
-13%
|
23 327
-22%
|
83 493
+258%
|
71 994
-14%
|
|
| Total Liabilities & Equity |
12 258
N/A
|
10 036
-18%
|
35 498
+254%
|
31 276
-12%
|
24 163
-23%
|
84 980
+252%
|
76 944
-9%
|
|
| Shares Outstanding | ||||||||
| Common Shares Outstanding |
9
|
17
|
20
|
20
|
20
|
23
|
23
|
|
Switch to:
Switch to:
See Also
Discover More
